MAPK3 and pancreatic neoplasm: To ascertain if the phosphorylation of ERK1/2 persisted in Pik3ca mutant pancreatic cancers following treatment with a dual PI3K/mTOR inhibitor, Pc1Pik3cap110* mice were treated with NVP-BEZ235, as above.